The incretin research landscape has moved faster in the last five years than in the previous two decades combined. Semaglutide established the foundation. Tirzepatide raised the bar with dual receptor agonism. Retatrutide pushed further still with triple agonism and Phase 2 weight loss data that hadn’t been seen before in the incretin class.
But the pipeline doesn’t stop at retatrutide. As of 2026, more than 100 weight-loss related compounds are in active development — over 35 of which incorporate a GLP-1 receptor agonist component. The field is moving in several directions simultaneously: more receptors, oral delivery, new hormonal combinations, and entirely new mechanisms. This article maps where the research is heading and what each development represents scientifically.
Research Use Educational Framework
- Educational reference content only
- Structural stability awareness
- Environmental handling considerations
- Analytical quality and purity awareness
- Non-clinical research context
The Generation Framework: How the Pipeline Evolved
Understanding where the pipeline is going requires understanding the generational structure it has followed. Each generation has added biological complexity to the foundation established by the previous one — and each addition has produced meaningfully different research outcomes.
Generation 1 — Single receptor GLP-1 agonists: Liraglutide and semaglutide. GLP-1 receptor only. Established the incretin research class and produced weight reductions in the 15–17% range in major trials. Semaglutide remains the established reference compound against which all subsequent generations are benchmarked.
Generation 2 — Dual receptor agonists: Tirzepatide (GLP-1 + GIP). Adding GIP receptor co-activation produced synergistic insulin response and pushed weight reduction outcomes to the 20–22% range in Phase 3 trials. Survodutide (GLP-1 + glucagon) represents a parallel dual agonist approach focused on liver biology rather than maximum weight endpoints.
Generation 3 — Triple receptor agonists: Retatrutide (GLP-1 + GIP + glucagon). Phase 2 data showed mean weight reductions of 24.2% at 48 weeks with no plateau observed — the highest efficacy data in the incretin research class to date. Phase 3 TRIUMPH program active.
Generation 4 — New combinations and delivery formats: CagriSema, orforglipron, once-monthly dosing candidates, and small molecule receptor agonists. This is where the pipeline is most active in 2026. For a full breakdown of how each existing compound works, our Tirzepatide vs Semaglutide article covers the foundational comparison in detail.
CagriSema: A Different Hormonal Combination
CagriSema — developed by Novo Nordisk — takes a fundamentally different approach to the multi-hormone question than the GIP/glucagon additions explored in generations 2 and 3. Instead of adding incretin receptors, it pairs semaglutide with cagrilintide — a long-acting analog of amylin, a pancreatic hormone that works through completely separate pathways from GLP-1.
Amylin is co-secreted with insulin from pancreatic beta cells in response to meals. It suppresses glucagon, slows gastric emptying, and reduces food intake through central nervous system pathways distinct from GLP-1’s hypothalamic signaling. The rationale for combining amylin and GLP-1 biology is that they produce complementary satiety signals through different neural circuits — potentially producing additive or synergistic effects on appetite regulation.
Phase 3 REDEFINE trial data for CagriSema showed mean weight loss of approximately 22.7% at 68 weeks — competitive with tirzepatide and representing a meaningful advance over semaglutide alone. An FDA response is expected in 2026, which would make CagriSema the first approved amylin/GLP-1 combination compound and open a new research category distinct from the incretin multi-agonist class. This is scientifically significant because it demonstrates that adding non-incretin hormonal pathways to GLP-1 agonism can produce outcomes comparable to dual and triple incretin receptor strategies.
Orforglipron: When GLP-1 Goes Small Molecule
Orforglipron — developed by Eli Lilly — represents the most structurally distinct development in the GLP-1 pipeline. It is not a peptide. It is a small molecule GLP-1 receptor agonist — a chemically synthesized non-peptide compound designed to activate the GLP-1 receptor through a binding mechanism different from peptide agonists.
This distinction matters enormously from a research and delivery perspective. Peptide-based GLP-1 agonists face the oral bioavailability challenge discussed in detail in our Oral Peptides Research article — their peptide structure makes them vulnerable to GI degradation. Small molecules don’t face this challenge in the same way, which is why orforglipron can be taken as a simple daily oral tablet without the SNAC technology required for oral semaglutide.
Phase 3 ATTAIN-1 trial data showed mean weight reduction of 11.2% with the highest dose at 72 weeks — lower than injectable GLP-1 agonists but achieved through a fully oral, once-daily small molecule format. An FDA decision on orforglipron for obesity was expected in the first half of 2026. If approved, it would be the second oral GLP-1 option available and the first non-peptide GLP-1 receptor agonist to reach the market — a landmark development that blurs the boundary between peptide pharmacology and small molecule drug design.
Once-Monthly Dosing: The Next Convenience Frontier
Beyond new mechanisms, one of the most active research directions in the GLP-1 pipeline is extended dosing intervals. Current approved GLP-1 compounds require weekly injections at minimum. Multiple development programs are actively pursuing once-monthly injectable formulations — a significant convenience improvement that research suggests could meaningfully improve real-world adherence.
Novo Nordisk has filed a supplemental application for higher-dose semaglutide — a 7.2mg weekly injectable dose that Phase 3 data suggests produces weight loss approaching 21% — pushing the ceiling of what first-generation single-receptor agonism can achieve. Separately, the Wegovy oral pill launched in January 2026, making once-weekly oral semaglutide a commercial reality for the first time.
The broader industry direction is clear — compounds are getting more potent, more convenient, and more diverse in mechanism simultaneously. The research implication is that investigators studying the GLP-1 class now have a wider range of compound profiles to work with than at any previous point in the field’s history. For researchers building familiarity with the incretin landscape, our compound-specific research overviews cover each generation in detail — starting with our Semaglutide Research Overview and progressing through Tirzepatide, Retatrutide, and Survodutide.
Where the Research Is Heading Beyond Weight
Perhaps the most scientifically significant development in the GLP-1 pipeline is the expansion beyond weight and glycemic endpoints into organ-specific disease indications. The field is discovering that GLP-1 receptor distribution across the body — heart, kidneys, brain, liver — means that sustained receptor activation produces biologically meaningful effects far beyond appetite and insulin regulation.
Active research programs in 2026 are investigating GLP-1 compounds in heart failure with preserved ejection fraction, chronic kidney disease, metabolic liver disease, obstructive sleep apnea, Alzheimer’s disease, Parkinson’s disease, and addiction models. Each of these represents a distinct receptor biology question — what happens when GLP-1 receptors in cardiac tissue, renal tissue, or neural tissue are chronically activated — and collectively they suggest the GLP-1 class may eventually be as important in organ protection research as it currently is in metabolic research.
BioStrata Research’s full Metabolic Research catalog includes research-grade incretin compounds — Sema — 10mg, Tirz — 10mg, and Reta — 10mg — for qualified laboratory research use.
FAQ — The GLP-1 Pipeline
What comes after retatrutide in the GLP-1 pipeline? The pipeline beyond retatrutide moves in several directions simultaneously — CagriSema adds amylin biology to GLP-1 agonism, orforglipron brings a small molecule non-peptide approach to GLP-1 receptor activation, and multiple programs are pursuing once-monthly dosing formats. The field is also expanding into organ-specific indications including heart failure, kidney disease, and neurological research well beyond the original metabolic endpoints.
What is CagriSema and how does it differ from tirzepatide? CagriSema combines semaglutide with cagrilintide — a long-acting amylin analog. Unlike tirzepatide which adds GIP receptor agonism to GLP-1 biology, CagriSema adds amylin pathway signaling — a completely different hormonal system that produces complementary satiety effects through distinct neural circuits. Phase 3 REDEFINE trial data showed mean weight loss of approximately 22.7% at 68 weeks.
What is orforglipron and why is it significant? Orforglipron is a small molecule GLP-1 receptor agonist — not a peptide — developed by Eli Lilly. Its non-peptide structure allows it to be taken as a simple daily oral tablet without the specialized formulation technology required for oral peptide delivery. An FDA decision was expected in the first half of 2026. If approved it would be the first non-peptide GLP-1 receptor agonist to reach the market.
How many GLP-1 compounds are currently in development? According to the BCG Biopharma Trends 2026 report, more than 100 weight-loss related compounds are currently in development, over 35 of which incorporate a GLP-1 receptor agonist component. The pipeline spans injectable peptides, oral peptides, small molecules, new hormonal combinations, and once-monthly dosing formats.
Where can I find detailed research overviews of individual GLP-1 compounds? BioStrata Research’s library covers each generation of the incretin class in dedicated compound overviews — Semaglutide, Tirzepatide, Retatrutide, and Survodutide.
- CONTINUE LEARNING
Explore Related Peptide Topics
Continue building your understanding by exploring related foundational peptide topics.